Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
Saved in:
| Title: | Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors. |
|---|---|
| Authors: | Rahma OE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Reuss JE; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Giobbie-Hurder A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts., Shoja E Razavi G; Cumming School of Medicine, University of Calgary, Calgary, Canada., Abu-Shawer O; Harvard Medical School, Boston, Massachusetts., Mehra P; University of Virginia, Charlottesville, Virginia., Gupta S; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Simon R; R Simon Consulting, Potomac, Maryland., Khleif SN; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. snk48@georgetown.edu. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jan 15; Vol. 27 (2), pp. 485-491. Date of Electronic Publication: 2020 Oct 20. |
| Publication Type: | Journal Article; Meta-Analysis |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 33082209 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Rahma+OE%22">Rahma OE</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Reuss+JE%22">Reuss JE</searchLink>; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.<br /><searchLink fieldCode="AU" term="%22Giobbie-Hurder+A%22">Giobbie-Hurder A</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Shoja+E+Razavi+G%22">Shoja E Razavi G</searchLink>; Cumming School of Medicine, University of Calgary, Calgary, Canada.<br /><searchLink fieldCode="AU" term="%22Abu-Shawer+O%22">Abu-Shawer O</searchLink>; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Mehra+P%22">Mehra P</searchLink>; University of Virginia, Charlottesville, Virginia.<br /><searchLink fieldCode="AU" term="%22Gupta+S%22">Gupta S</searchLink>; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.<br /><searchLink fieldCode="AU" term="%22Simon+R%22">Simon R</searchLink>; R Simon Consulting, Potomac, Maryland.<br /><searchLink fieldCode="AU" term="%22Khleif+SN%22">Khleif SN</searchLink>; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. snk48@georgetown.edu. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2021 Jan 15; Vol. 27 (2), pp. 485-491. <i>Date of Electronic Publication: </i>2020 Oct 20. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Meta-Analysis – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33082209 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1158/1078-0432.CCR-20-2669 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 485 Titles: – TitleFull: Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Rahma OE – PersonEntity: Name: NameFull: Reuss JE – PersonEntity: Name: NameFull: Giobbie-Hurder A – PersonEntity: Name: NameFull: Shoja E Razavi G – PersonEntity: Name: NameFull: Abu-Shawer O – PersonEntity: Name: NameFull: Mehra P – PersonEntity: Name: NameFull: Gupta S – PersonEntity: Name: NameFull: Simon R – PersonEntity: Name: NameFull: Khleif SN IsPartOfRelationships: – BibEntity: Dates: – D: 15 M: 01 Text: 2021 Jan 15 Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 1557-3265 Numbering: – Type: volume Value: 27 – Type: issue Value: 2 Titles: – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research Type: main |
| ResultId | 1 |
